Cell Therapy Manufacturing Automation Market Global Report 2026

The cell therapy manufacturing automation market size has grown rapidly in recent years. It will grow from $1.82 billion in 2025 to $2.1 billion in 2026 at a compound annual growth rate (CAGR) of 15.2%. The growth in the historic period can be attributed to rising demand for cell processing solutions, increasing requirements for scalable manufacturing, growing adoption of automated bioreactor systems, expansion of GMP-compliant production workflows, and greater emphasis on consistent manufacturing outcomes.

The cell therapy manufacturing automation market size is expected to see rapid growth in the next few years. It will grow to $3.63 billion in 2030 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to increasing volumes of personalized therapies, rising investments in automation technologies, growing requirements for contamination-free processing workflows, expansion of commercial-scale manufacturing operations, and increasingly stringent regulatory quality requirements. Major trends in the forecast period include continued technological advancements in closed processing systems, automation-led process improvements, development of integrated manufacturing workflows, increasing research into real-time analytics, and advancement of robotics technologies for therapy manufacturing.

The growing demand for gene therapies is anticipated to drive the growth of the cell therapy manufacturing automation market going forward. Gene therapy refers to a medical technique that involves modifying, replacing, or introducing genes to treat or prevent diseases. The increasing demand for gene therapy is driven by advancements in genetic sequencing and diagnostics, which enable the precise identification of disease-causing genes for targeted treatments. Cell therapy manufacturing automation supports gene therapy by streamlining and standardizing complex manufacturing processes, ensuring consistent quality and scalability. It enhances therapeutic development by minimizing errors, improving operational efficiency, and enabling reliable large-scale manufacturing of gene-modified cells. For instance, in December 2024, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, the Food and Drug Administration (FDA) approved six gene therapy products in 2023, compared with five approvals in 2022. Therefore, the growing demand for gene therapies is driving the growth of the cell therapy manufacturing automation market.

Leading companies operating in the cell therapy manufacturing automation market are concentrating on developing advanced solutions, such as automated cell therapy systems, to connect multi-stage manufacturing workflows within unified and validated digital frameworks that reduce manual touchpoints and support regulatory compliance. An automated cell therapy system refers to an off-the-shelf validated automation solution that digitally integrates cell therapy instruments, including magnetic separation systems, centrifugation equipment, electroporation systems, and incubators, through a single interface, enabling traceability, repeatability, and cGMP compliance across manufacturing stages. For example, in January 2024, Thermo Fisher Scientific Inc., a US-based life sciences company, launched Gibco CTS Cellmation Software, a first-of-its-kind automation solution. It is an off-the-shelf validated software solution that digitally connects instruments across Thermo Fisher's cell therapy portfolio to automate manufacturing workflows. The solution incorporates a pre-validated automation system powered by Emerson's DeltaV technology, enabling seamless integration and control of multiple instruments without requiring costly custom projects, while establishing traceable and repeatable workflows that support cGMP and data security compliance and reduce manual touchpoints for cell therapy developers.

In July 2024, Cellular Origins Ltd., a UK-based provider of automated cell and gene therapy manufacturing solutions, acquired the intellectual property (IP) of the Autologous Cell Therapy Industrial Automation (ACTIA) Platform for an undisclosed amount. Through this acquisition, Cellular Origins strengthened its automated manufacturing technology portfolio by further developing the Constellation robotic platform to enhance scalability, minimize production bottlenecks, and facilitate industrialized cell therapy manufacturing processes. The ACTIA Platform IP is a US-based intellectual property platform designed specifically for industrial automation applications in autologous cell therapy manufacturing.

Major companies operating in the cell therapy manufacturing automation market are Thermo Fisher Scientific Inc., Merck KGaA, Fujifilm Holdings Corporation, Corning Incorporated, Lonza Group AG, Cytiva, WuXi AppTecCo. Ltd., Hitachi High Technologies Corp., CatalentInc., Sartorius AG, Beckman Coulter Life Sciences, Terumo BCT Inc., Miltenyi Biotec, Oxford Biomedica Plc, National Resilience LLC, Minaris Regenerative Medicine LLC, Tulip Interfaces Inc., Invetech Pty Ltd., BlueRock Therapeutics LLC, Cellares Inc., Ascential Medical & Life Sciences, Cell and Gene Therapy Catapult.

North America was the largest region in the cell therapy manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell therapy manufacturing automation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cell therapy manufacturing automation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 1-3 business days.